LONDON--(BUSINESS WIRE)--Jul 23, 2018--Technavio has announced their latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat the Guillain-Barre syndrome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180723005534/en/
Technavio has published a new report on the drug development pipeline for Guillain-Barre syndrome, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Guillain-Barre syndrome: Market overview
Guillain-Barre syndrome (GBS) is an autoimmune disorder in which the immune system mistakenly attacks healthy nerve cells, thus leading to weakness in the muscles, numbness, and tingling. It can eventually cause paralysis. The immune system destroys the myelin sheath surrounding the axons of peripheral nerves, which carry nerve signals. Nerve cells start losing the ability to transmit signals efficiently when myelin sheath is injured. The actual cause of GBS is unknown, but it usually occurs a few days after a patient had symptoms of a respiratory or gastrointestinal viral infection. Zika virus infection is also linked to GBS.
According to a senior market research analyst at Technavio, “According to the Centers for Disease Control and Prevention report in August 2016, GBS is associated with Zika and in many countries where the population is affected with Zika, have reported an increase in GBS patient population. CDC also stated that every year, approximately 3,000-6,000 people in the US develop GBS. With the increase in the age, the incidences of GBS also increases. As a result, with the rising incidences of the disease, the requirement for the drug development for Guillain-Barre syndrome is expected to increase in the upcoming years.”
Guillain-Barre syndrome: Segmentation analysis
This pipeline analysis report segments the Guillain-Barre syndrome market based on therapies employed (monotherapy), RoA (oral, intravenous, and subcutaneous), therapeutic modality (monoclonal antibody, enzyme, peptide, and recombinant protein), targets (complement component-5, cannabinoid receptor, complement component-1 q, and complement component-6), MoA (complement component-5 inhibitor, cannabinoid receptor agonists, complement component-1 q inhibitor, and complement component-6 inhibitor, and immunosuppressants), geographical segmentation (Japan) and recruitment status (completed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, around 43% of the molecules that are being investigated for the treatment of Guillain-Barre syndrome are monoclonal antibody.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180723005534/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA MIDDLE EAST
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES RESEARCH SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/23/2018 12:13 PM/DISC: 07/23/2018 12:13 PM